Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital
Retrieved on:
Wednesday, February 16, 2022
Gram-negative bacteria, Pyelonephritis, HAP, Lung, Clinical trial, BAL, Assistant Secretary of Defense for Health Affairs, U.S. Securities and Exchange Commission, Therapy, Acquisition, Pharmacokinetics, MDR, COVID-19, QIDP, Health, Degenerative disease, United, Investor, Gram, Cutis verticis gyrata, AUC, Centers for Disease Control and Prevention, Fort Detrick, AM, Research, Spero, Tablet, Infection, HBR, Urinary tract infection, Nasdaq, Safety, ELF, Nephrotoxicity, World Health Organization, GLOBE, Patient, VAP, Tebipenem, United States federal executive departments, FDA, Plasma, NDA, Bacterial outer membrane, Growth, Assistant, Pharmaceutical industry, Defense
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate. SPR206 was derived from Spero’s potentiator platform and is in development to treat serious multi-drug resistant (MDR) gram-negative infections in the hospital setting.
Key Points:
- SPR206 was derived from Speros potentiator platform and is in development to treat serious multi-drug resistant (MDR) gram-negative infections in the hospital setting.
- The Phase 1 BAL study evaluated the safety and pharmacokinetics (PK) of SPR206 when administered at 100 mg, three times daily.
- Together with our prior Phase 1 and pre-clinical data, we look forward to engaging with regulators as we plan the continued development of SPR206.
- The Phase 1 BAL clinical trial was an open-label study designed to enroll 30 healthy volunteers into five cohorts.